...
首页> 外文期刊>British journal of ophthalmology >Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?
【24h】

Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?

机译:勃起功能障碍药物和前部缺血性视神经病变的风险:偶然还是因果关系?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Phosphodiesterase type 5 (PDE5) inhibitor drugs for erectile dysfunction have revolutionised the treatment of male sexual dysfunction and are among the best selling drugs worldwide. Several cases of non-arteritic anterior ischaemic optic neuropathy (NAION) have been reported since 2005 in users of these agents. NAION is a sudden irreversible cause of visual loss with a poorly understood aetiology that affects up to 10 adults per 100,000 each year. Following a series of such case reports, WHO and FDA have labelled the association between use of PDE5 inhibitors and risk of NAION as "possibly" causal. There have been several recent studies of this association, including a rechallenge case report and a large managed care database study. However, the inability to confirm or refute claims of an association between NAION and EDD is generating clinical and regulatory uncertainty. Questions surrounding use of PDE5 inhibitors and risk of NAION highlight weaknesses in current systems used to identify and evaluateuncommon adverse effects of medication use. This paper reviews all the recent evidence on PDE5 inhibitors and the risk of NAION.
机译:用于勃起功能障碍的5型磷酸二酯酶(PDE5)抑制剂药物彻底改变了男性性功能障碍的治疗方法,并且是全世界最畅销的药物之一。自2005年以来,已经报道了使用这些药物的用户的非动脉性前部缺血性视神经病变(NAION)的几例。 NAION是一种突然的不可逆的视力丧失原因,其病因学知之甚少,每年影响每10万名成年人中多达10名成年人。在一系列此类病例报告之后,WHO和FDA将PDE5抑制剂的使用与NAION风险之间的关联标记为“可能”的因果关系。该协会最近有几项研究,包括再挑战病例报告和大型管理式护理数据库研究。但是,无法确认或驳斥NAION与EDD之间关联的主张正在产生临床和法规不确定性。围绕PDE5抑制剂的使用和NAION风险的问题凸显了当前用于识别和评估罕见的药物不良反应的系统的缺陷。本文回顾了有关PDE5抑制剂和NAION风险的所有最新证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号